Heron Therapeutics, Inc.

HRTX Healthcare Biotechnology

Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024. In the quarter to June 2026, revenue grew 1.25%, EPS fell 93.6%, free cash flow grew 78.8% and total debt fell 18.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

0.36 0.02 −5.26%
Market cap
$71.5M
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
4/9
Altman Z
−8.84
Beneish M
−2.40
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 4 4 2 3 4 3 3 4
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(16.72) (0.96) 9.25 7.23 3.17 (6.37) (10.61) (11.92) (9.94) (8.84)
P/S ratio
0.00 32.49 24.51 13.17 21.68 10.41 2.46 2.06 1.62 1.40
Altman Z″-Score (non-manufacturers)
(43.30) (11.65) (0.19) (1.39) (11.13) (17.70) (24.72) (28.19) (24.00) (21.08)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(13.19) (21.20) (56.70) (71.24) (36.57) (19.86) (7.05) 106.34 (19.80) (23.60)
Beneish M-Score
— 17.62 (1.11) 16.86 (2.83) (2.79) (2.77) (3.56) (2.31) (2.40)
P/B ratio
0.00 7.62 5.13 4.76 8.13 11.59 19.49 0.00 0.00 16.32
Price to Tangible BV
0.00 7.62 5.13 4.76 8.13 11.59 19.49 0.00 0.00 16.32
EV/Sales
0.00 27.70 20.54 10.57 19.49 10.31 3.06 2.79 2.42 2.01
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(3.78) (5.01) (8.30) (12.39) (9.35) (4.38) (2.24) (6.03) (15.48) (11.26)
EV/FCF
(3.69) (4.93) (7.92) (11.71) (9.02) (4.32) (2.22) (5.88) (14.26) (11.17)
Quick Ratio
1.37 2.08 4.31 4.46 2.44 2.72 1.66 1.76 1.51 1.42
Current Ratio
1.60 2.21 4.86 4.95 3.07 3.58 2.49 2.37 2.29 2.48
Net Debt/EBITDA
0.01 0.90 1.80 1.79 0.87 0.04 (0.37) (0.86) (11.30) (643.88)
Debt/Assets
74.09% 0.00% 0.00% 2.39% 4.12% 48.77% 59.49% 78.09% 74.94% 54.96%
Debt/Equity
(2.35) 0.00 0.00 0.03 0.06 1.92 11.00 (5.11) (5.19) 9.81
Asset Turnover
0.01 0.20 0.22 0.30 0.20 0.26 0.39 0.54 0.63 0.63
Operating CF/Net income
0.77 0.86 1.07 0.61 0.81 0.92 0.81 0.53 1.66 1.37
Capex/Depreciation
(1.52) (1.22) 9.06 11.25 (1.55) (0.70) (0.68) (1.02) (1.28) (0.09)
Interest Coverage
(64.16) (49.42) (68.84) (143.13) (120.02) (90.39) (70.60) (28.60) (1.91) (0.26)
ROE
(357.52%) (359.44%) (71.35%) (52.91%) (70.99%) (140.53%) (399.43%) 1,083.86% 40.16% 198.30%
ROA
(168.65%) (130.88%) (51.35%) (42.00%) (52.47%) (66.95%) (65.40%) (46.70%) (5.96%) (8.26%)
ROIC
0.00% 0.00% (304.22%) (524.53%) (335.05%) (197.10%) (139.94%) (116.44%) (8.81%) (1.46%)
Return on Tangible Assets
(607.82%) (150.90%) (48.35%) (50.94%) (96.95%) (106.56%) (125.33%) (85.54%) (10.26%) (13.08%)
Average Days of Receivables
559.34 496.77 304.59 99.72 172.33 150.06 176.44 172.77 199.55 211.09
Research and Development Expense of Revenue
8,062.94% 450.42% 180.75% 114.67% 196.91% 151.51% 76.81% 30.80% 11.56% 8.02%
Selling, General and Administrative Expense of Revenue
5,397.50% 267.02% 121.16% 87.46% 119.68% 147.47% 134.44% 105.02% 69.64% 66.92%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
2,029.40% 99.26% 43.07% 35.22% 56.66% 54.26% 39.92% 25.86% 8.98% 6.67%
Graham Net Nets
(0.05) 0.12 0.19 0.19 0.10 0.03 (0.12) (0.26) (0.25) (0.02)
Graham Number
7.57 0.00 0.00 0.00 0.00 0.00 0.00 2.18 0.67 0.00
Earnings Yield
(33.96%) (19.78%) (9.52%) (10.64%) (11.81%) (24.64%) (71.19%) (45.50%) (5.88%) (8.88%)
Free Cash Flow Yield
(27.00%) (17.28%) (10.58%) (6.85%) (9.97%) (22.95%) (56.13%) (23.10%) (10.48%) (12.83%)
Revenue per Share
0.03 0.57 1.06 1.78 0.98 0.88 0.99 0.92 0.95 0.93
Operating CF per Share
(3.54) (3.15) (2.62) (1.52) (2.04) (2.07) (1.35) (0.43) (0.15) (0.17)
Capex per Share
(0.08) (0.05) (0.12) (0.09) (0.08) (0.03) (0.01) (0.01) (0.01) 0.00
Free Cash Flow per Share
(3.62) (3.20) (2.75) (1.61) (2.11) (2.10) (1.36) (0.44) (0.16) (0.17)
Cash per Share
1.35 3.19 4.54 4.78 2.30 1.60 0.78 0.58 0.39 0.28
Shareholders Equity per Share
(0.56) 2.43 5.06 4.94 2.61 0.79 0.12 (0.25) (0.22) 0.09
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.56) 2.43 5.06 4.94 2.61 0.79 0.12 (0.25) (0.22) 0.09
Free Cash Flow
(137.23) (172.77) (200.95) (131.73) (191.63) (206.34) (148.51) (60.32) (24.21) (27.81)
Working Capital
23.41 124.89 355.23 382.36 211.69 183.37 123.08 109.09 117.56 141.97
Capital Expenditures
(3.13) (2.47) (9.15) (7.15) (6.81) (2.99) (1.60) (1.53) (1.68) (0.22)
Net Current Asset Value
(26.59) 124.89 355.23 370.12 197.13 26.29 (31.94) (67.70) (57.78) (3.48)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
2.45 0.08 0.12 0.05 0.08 0.03 0.01 0.01 0.01 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.41 0.34 (0.07) (0.03) 0.19 0.18 0.11 0.07 0.09 0.19
Cash ROIC
(171.78%) (56.92%) (28.60%) (16.32%) (41.70%) (53.70%) (59.95%) (27.40%) (12.08%) (13.79%)
Accounts Receivable Turnover
1.24 1.40 1.45 2.79 2.17 2.23 2.46 2.26 2.08 1.84
Accounts Payable Turnover
0.01 0.36 1.54 6.28 22.05 21.27 15.62 20.14 5.17 3.99
Inventory Turnover
0.00 0.59 1.12 1.93 1.08 1.02 1.07 1.35 0.81 0.57
Average Days of Payables
71,060.29 1,493.17 223.72 16.34 5.30 30.16 21.45 18.16 110.58 79.40
Days of Inventory on Hand
55,688.57 804.15 517.84 147.90 422.65 383.73 363.00 236.08 502.05 818.74
Average Receivables
1.04 21.92 53.26 52.27 40.86 38.67 43.77 56.09 69.51 84.23
Average Payables
5.06 12.79 17.82 9.81 1.64 2.16 3.51 3.23 7.47 10.35
Average Inventory
7.72 7.72 24.57 32.00 33.44 45.14 51.48 48.34 47.64 72.95
Average Assets
102.66 150.89 348.24 487.48 433.17 329.63 278.33 236.73 227.83 244.51
Average Common Equity
48.43 54.94 250.65 387.00 320.16 157.03 45.57 (10.20) (33.81) (10.18)

Fold the line items

Columns are period end dates